Zhongshan city Peaple's Hospital
Welcome,         Profile    Billing    Logout  
 0 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lei, Feng
NCT06239727: Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Recruiting
3
593
RoW
PD-1 blocking antibody, Camrelizumab, Gemcitabine, GEM, Cisplatin (80 mg/m2), DDP, Reduced-dose Intensity-modulated radiotherapy, Reduced-dose IMRT, Conventional-dose Intensity-modulated radiotherapy, Conventional-dose IMRT, Cisplatin (100 mg/m2), Capecitabine
Sun Yat-sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
02/27
02/30
NCT06749899: QL1706 (IPD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Recruiting
3
580
RoW
QL1706, Gemcitabine, Cisplatin, Intensity-modulated radiotherapy
Sun Yat-sen University, Qilu Pharmaceutical Co., Ltd.
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
12/28
12/30
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Recruiting
2
238
RoW
MRG003, Capecitabine tablets, Docetaxel injection
Shanghai Miracogen Inc.
Recurrent or Metastatic Nasopharyngeal Carcinoma
10/24
02/25
NCT06479343: Efficacy and Safety of the Liquid Embolic System (Tonbridge) for Endovascular Treatment of Cerebrovascular Malformations

Recruiting
N/A
170
RoW
Liquid Embolic System (Tonbridge), Onyx Liquid Embolic System (Medtronic)
Zhuhai Tonbridge Medical Tech. Co., Ltd.
Intracranial Arteriovenous Malformations
10/25
10/26
Yang, Kaibin
NCT06239727: Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Recruiting
3
593
RoW
PD-1 blocking antibody, Camrelizumab, Gemcitabine, GEM, Cisplatin (80 mg/m2), DDP, Reduced-dose Intensity-modulated radiotherapy, Reduced-dose IMRT, Conventional-dose Intensity-modulated radiotherapy, Conventional-dose IMRT, Cisplatin (100 mg/m2), Capecitabine
Sun Yat-sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
02/27
02/30

Download Options